Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma

Sponsor
Beijing Children's Hospital
Study ID
NCT06818916
Status
Recruiting
Apply to this trial

Conditions

  • Autologous Hematopoietic Stem Cell Transplantation
  • Delayed Platelet Engraftment
  • Neuroblastoma

Eligibility Criteria

Sex
ALL
Age
N/A - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Hetrombopag — DRUG
    Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.

Study Details

The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.

Key Dates

First listed
Feb 11, 2025
Start date
Jun 30, 2024
Status verified
Nov 2025
Primary completion
Apr 30, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Experimental group

Primary Outcome Measure

Accumulated platelet engraftment rate [ Time Frame: From enrollment to 60 days post-transplant ]

Central Contacts

Find similar trials

Nationwide
Neuroblastoma trialsOncology trialsPediatric oncology trials

Related Studies